Technical Analysis for RVNC - Revance Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 14.0 -3.45% -0.50
RVNC closed down 3.45 percent on Wednesday, September 18, 2019, on 1.37 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical RVNC trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New Uptrend Bullish -3.45%
Pocket Pivot Bullish Swing Setup -3.45%
Wide Range Bar Range Expansion -3.45%
Upper Bollinger Band Walk Strength -3.45%
Wide Bands Range Expansion -3.45%
Above Upper BB Strength -3.45%

Older signals for RVNC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.
Biopharmaceutical Pain Drugs Migraine Plastic Surgery Toxins Botulinum Toxin Botulism Hyperhidrosis Neurotoxins Prevention Of Migraine Rhinitis
Is RVNC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 26.89
52 Week Low 10.0
Average Volume 359,302
200-Day Moving Average 14.6756
50-Day Moving Average 11.9396
20-Day Moving Average 11.6465
10-Day Moving Average 12.64
Average True Range 0.6605
ADX 27.65
+DI 37.0115
-DI 11.16
Chandelier Exit (Long, 3 ATRs ) 12.578
Chandelier Exit (Short, 3 ATRs ) 11.9815
Upper Bollinger Band 14.2918
Lower Bollinger Band 9.0012
Percent B (%b) 0.94
BandWidth 45.426523
MACD Line 0.5861
MACD Signal Line 0.1905
MACD Histogram 0.3956
Fundamentals Value
Market Cap 431.47 Million
Num Shares 30.8 Million
EPS -3.44
Price-to-Earnings (P/E) Ratio -4.07
Price-to-Sales 2609.34
Price-to-Book 4.85
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.62
Resistance 3 (R3) 15.63 15.09 15.35
Resistance 2 (R2) 15.09 14.68 15.09 15.26
Resistance 1 (R1) 14.55 14.43 14.28 14.54 15.17
Pivot Point 14.01 14.01 13.88 14.01 14.01
Support 1 (S1) 13.47 13.60 13.20 13.46 12.83
Support 2 (S2) 12.93 13.35 12.93 12.74
Support 3 (S3) 12.39 12.93 12.65
Support 4 (S4) 12.38